Stock PROK PROKIDNEY CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases ProKidney Corp.

Equities

PROK

KYG7S53R1049

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-07-04 pm EDT 		5-day change 1st Jan Change
2.25 USD -3.43% Intraday chart for ProKidney Corp. -8.54% +26.40%
Jun. 17 ProKidney Closes Public, Registered Direct Offerings MT
Jun. 12 ProKidney Prices Upsized $130 Million Stock Offering MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters Option
AQ
ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
AQ
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
AQ
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
AQ
ProKidney : Corporate Update Conference Call Presentation
PU
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
AQ
ProKidney to Participate in the Jefferies Global Healthcare Conference
AQ
ProKidney : Virtual KOL Presentation
PU
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
AQ
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
AQ
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
AQ
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
AQ
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
AQ
ProKidney to Participate in Jefferies Biotech on the Bay Summit
AQ
Chronic Kidney Disease Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, and others.
AQ
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
AQ
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
AQ
ProKidney Reports Third Quarter Financial Results
AQ
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
AQ
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PROK Stock
  4. News ProKidney Corp.
  5. Press Releases